Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP427738.RABadr_fh_3GjLqlbjveguYJ4aIIabL7fC8XuhWdTgE5c130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP427738.RABadr_fh_3GjLqlbjveguYJ4aIIabL7fC8XuhWdTgE5c130_assertion type Assertion NP427738.RABadr_fh_3GjLqlbjveguYJ4aIIabL7fC8XuhWdTgE5c130_head.
- NP427738.RABadr_fh_3GjLqlbjveguYJ4aIIabL7fC8XuhWdTgE5c130_assertion description "[Our experimental results have revealed that gefitinib additively enhances the antitumor effect of fulvestrant in estrogen receptor (ER)-positive breast cancer cells under estrogen-supplemented conditions.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP427738.RABadr_fh_3GjLqlbjveguYJ4aIIabL7fC8XuhWdTgE5c130_provenance.
- NP427738.RABadr_fh_3GjLqlbjveguYJ4aIIabL7fC8XuhWdTgE5c130_assertion evidence source_evidence_literature NP427738.RABadr_fh_3GjLqlbjveguYJ4aIIabL7fC8XuhWdTgE5c130_provenance.
- NP427738.RABadr_fh_3GjLqlbjveguYJ4aIIabL7fC8XuhWdTgE5c130_assertion SIO_000772 14718791 NP427738.RABadr_fh_3GjLqlbjveguYJ4aIIabL7fC8XuhWdTgE5c130_provenance.
- NP427738.RABadr_fh_3GjLqlbjveguYJ4aIIabL7fC8XuhWdTgE5c130_assertion wasDerivedFrom befree-2016 NP427738.RABadr_fh_3GjLqlbjveguYJ4aIIabL7fC8XuhWdTgE5c130_provenance.
- NP427738.RABadr_fh_3GjLqlbjveguYJ4aIIabL7fC8XuhWdTgE5c130_assertion wasGeneratedBy ECO_0000203 NP427738.RABadr_fh_3GjLqlbjveguYJ4aIIabL7fC8XuhWdTgE5c130_provenance.